title: Elucidation of the relationship between synovitis and bone damage: a randomized magnetic resonance imaging study of individual joints in patients with early rheumatoid arthritis.
abstract: OBJECTIVE
  To simultaneously image bone and synovium in the individual joints characteristically involved in early rheumatoid arthritis (RA).
  
  
  METHODS
  Forty patients with early, untreated RA underwent gadolinium-enhanced magnetic resonance imaging (MRI) of the second through fifth metacarpophalangeal joints of the dominant hand at presentation, 3 months, and 12 months. In the first phase (0-3 months), patients were randomized to receive either methotrexate alone (MTX) or MTX and intraarticular corticosteroids (MTX + IAST) into all joints with clinically active RA. The MTX-alone group received no further corticosteroids until the second phase (3-12 months), when both groups received standard therapy.
  
  
  RESULTS
  In the first phase, MTX + IAST reduced synovitis scores more than MTX alone. There were significantly fewer joints with new erosions on MRI in the former group compared with the latter. During the second phase, the synovitis scores were equivalent and a similar number of joints in each group showed new erosions on MRI. In both phases, there was a close correlation between the degree of synovitis and the number of new erosions, with the area under the curve for MRI synovitis the only significant predictor of bone damage progression. In individual joints, there was a threshold effect on new bone damage related to the level of synovitis; no erosions occurred in joints without synovitis.
  
  
  CONCLUSIONS
  In early RA, synovitis appears to be the primary abnormality, and bone damage occurs in proportion to the level of synovitis but not in its absence. In the treatment of patients with RA, outcome measures and therapies should focus on synovitis.
authors.affiliation: University of Leeds and Leeds General Infirmary, Leeds, UK.
authors.forename: Philip G
authors.initials: PG
authors.lastname: Conaghan
authors.forename: Philip
authors.initials: P
authors.lastname: O'Connor
authors.forename: Dennis
authors.initials: D
authors.lastname: McGonagle
authors.forename: Paul
authors.initials: P
authors.lastname: Astin
authors.forename: Richard J
authors.initials: RJ
authors.lastname: Wakefield
authors.forename: Wayne W
authors.initials: WW
authors.lastname: Gibbon
authors.forename: Mark
authors.initials: M
authors.lastname: Quinn
authors.forename: Zunaid
authors.initials: Z
authors.lastname: Karim
authors.forename: Michael J
authors.initials: MJ
authors.lastname: Green
authors.forename: Susanna
authors.initials: S
authors.lastname: Proudman
authors.forename: John
authors.initials: J
authors.lastname: Isaacs
authors.forename: Paul
authors.initials: P
authors.lastname: Emery
mesh_terms: D000305:Adrenal Cortex Hormones / Q000008:administration & dosage; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D018501:Antirheumatic Agents / Q000008:administration & dosage; D001172:Arthritis, Rheumatoid / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000473:pathology*; D004487:Edema / Q000000981:diagnostic imaging / Q000188:drug therapy / Q000473:pathology; D005260:Female; D006801:Humans; D007270:Injections, Intra-Articular; D008279:Magnetic Resonance Imaging; D008297:Male; D008662:Metacarpophalangeal Joint / Q000000981:diagnostic imaging / Q000473:pathology*; D008727:Methotrexate / Q000008:administration & dosage; D008875:Middle Aged; D011859:Radiography; D013585:Synovitis / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000473:pathology*; D016896:Treatment Outcome
chemical_list: D000305:Adrenal Cortex Hormones; D018501:Antirheumatic Agents; D008727:Methotrexate